Efficacy and safety of intrathecal pemetrexed for treating leptomeningeal metastasis from lung adenoma cancer: Phase I clinical trial

Conditions

lung cancer

Xiaowei Song, Chong Teng, Siqi Man, Chengjuan Fan, Bo Wang et al. (8 authors)

Journal of Clinical Oncology2026-06-23

10.1200/jco.2026.44.19_suppl.265

Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial.

Xu Q, Huang K, Tong L, Yan D, Zhao Y, Yang H, Jin W, Zhang L, Cai J, Chen Q.

2025-05-28

10.1186/s12916-025-04134-7

Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial.

Fan C, Jiang Z, Teng C, Song X, Li L, Shen W, Jiang Q, Huang D, Lv Y, Du L, Wang G, Hu Y, Man S, Zhang Z, Gao N, Wang F, Shi T, Xin T.

2024-02-1924 citations

10.1016/j.esmoop.2024.102384

Interventions

Case series:intrathecal pemetrexed

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with meningeal metastasis from lung adenocarcinoma; 2. ECOG PS 0-2; 3. Aged 18 to 75 years; 4. Multiline treatment failures, including systemic chemotherapy or TKI treatment or receiving methotrexate and cytarabine intrathecal chemotherapy; 5. adequate organ function (absolute neutrophil count =1500/mm3, platelet count=100,000/mm3, hemoglobin concentration =9.0g/dL, serum total bilirubin concentration =1.5 mg/dL, serum transaminase concentration =2.5 times the upper normal limit, serum creatinine concentration =1.5 times the upper normal limit, SpO2 =90% on room air, and proteinuria =1+).

Exclusion criteria

Exclusion criteria: 1. HIV-positive patients; 2. history of severe pemetrexed allergies; 3. severe infection or severe comorbidities such as bleeding peptic ulcer, ileus, heart failure, renal failure, or poorly controlled diabetes; 4. Failure to observe test requirements; 5. Pregnancy (verified by serum or urine ß-human chorionic gonadotropin [ß-HCG]) or lactation.

Design outcomes

Primary

Measure	Time frame
Os;	—

Countries

China

Contacts

Public ContactTao Xin

the 2nd Affliated Hospital of Harbin Medical University

taoxinemail@126.com+86 13633655999

Outcome results

None listed